Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature
Authors:
- 2 July 2014
- journal article
- case report
- Published by Wiley in European Journal of Haematology
- Vol. 94 (6) , 554-557
Abstract
Brentuximab Vedotin is an antibody – drug conjugate targeting CD30. We report a case of severe cytokine release syndrome (CRS) after administration of the first dose of Brentuximab Vedotin in a 64‐yr‐old patient with relapsed systemic anaplastic large cell lymphoma (sALCL). To our knowledge, this is the first case of CRS to Brentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet.Keywords
This publication has 14 references indexed in Scilit:
- Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literatureJournal of Medical Case Reports, 2013
- CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic MalignanciesThe Journal of Clinical Pharmacology, 2013
- Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantationJournal of Oncology Pharmacy Practice, 2012
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II StudyJournal of Clinical Oncology, 2012
- Rituximab and Cytokine Release SyndromeCase Reports in Oncology, 2012
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic MalignanciesClinical Cancer Research, 2012
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Management and Preparedness for Infusion and Hypersensitivity ReactionsThe Oncologist, 2007
- Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's diseaseCell, 1992